SEroma Reduction pOst MAstectomy "SEROMA Study" (SEROMA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03738527 |
|
Recruitment Status :
Recruiting
First Posted : November 13, 2018
Last Update Posted : February 21, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a pilot study to evaluate the feasibility of conducting a larger trial to determine if the use of intraoperative topical tranexamic acid (TXA) decreases the rate of post-operative hematomas and seromas in breast cancer patients after their mastectomy. In other words, the investigators want to determine if applying TXA inside the surgical wound before it is closed helps reduce blood or serous fluid accumulation at the operative site. Dependent on the results of this study, a further larger trial may or may not take place.
Post-operative seromas and hematomas are common complications of mastectomy surgery not only leading to infection, discomfort, wound dehiscence or emergency room visits; they also delay in some instances post-operative adjuvant radiotherapy. Establishing whether or not topical TXA is an effective strategy to decrease those complications can potentially impact positively the breast cancer treatment.
To achieve this aim, this randomized pilot study will first determine whether a larger multicenter study if feasible. This study will replicate a formal randomized trial at a smaller scale in a single center in order to assess the recruitment and randomization process, as well as provide preliminary results for our research question.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Seroma Complicating A Procedure Hematoma Postoperative Breast Cancer | Drug: Tranexamic Acid 100mg/mL, 20mL topical Drug: Normal Saline Flush, 0.9%, 20mL topical | Phase 4 |
The objective of this study is to investigate the novel use of topical application of Tranexamic Acid (TXA) to the surgical wound as a means to decrease seroma and/or hematoma formation compared to placebo in post-mastectomy patients. This project is designed as a single-center pilot RCT to evaluate the feasibility of conducting a formal RCT (multicenter trial including more patients) to evaluate the effectiveness of topical TXA.
Patients will be randomly assigned to one of two treatment groups for intraoperative treatment of their mastectomy wound before it is closed.
The first group will consist of those who will be treated with the intravenous form of TXA that will be applied to the surface of the mastectomy wound area rather than being injected into a vein. The second group consists of those individuals who will be treated with a topical normal saline solution (a placebo, or inactive substance that looks identical to the study drug but contains no therapeutic ingredients).
Both groups will receive the same number of drains and the same post-operative follow-up schedule consisting of visits 2 to 4 weeks and 3 months after the surgery, as well as a last 12 months follow-up. Standard of care will be practiced with respect to all procedures and visits.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Pilot Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo). Intervention: Topical application of 20 mL of TXA (100 mg/mL injection solution) to the mastectomy cavity Placebo: Topical application of 20 mL of 0.9% NaCl (normal saline) to the mastectomy cavity |
| Masking: | Double (Participant, Care Provider) |
| Masking Description: | Patients will be randomized on the REDCap system. Their assignment will be made available to pharmacy, which will be prepare syringes with either TXA or placebo. |
| Primary Purpose: | Prevention |
| Official Title: | Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention |
| Actual Study Start Date : | October 7, 2019 |
| Estimated Primary Completion Date : | January 2022 |
| Estimated Study Completion Date : | July 2022 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: TXA arm |
Drug: Tranexamic Acid 100mg/mL, 20mL topical
Drug: Tranexamic Acid 20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure |
| Placebo Comparator: Placebo arm |
Drug: Normal Saline Flush, 0.9%, 20mL topical
Drug: Normal Saline 20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure |
- Recruitment rate [ Time Frame: About 6 months ]Number of patients recruited over the total number of eligible patients screened
- Randomization rate [ Time Frame: About 9 months ]Number of patients randomized over total number recruited
- Follow-up visit rate [ Time Frame: 3 months ]Number of patients with successful follow-up visits at 3 weeks and 3 months
- Ability to adhere to protocol [ Time Frame: About 12 months ]Number of patients randomized to TXA who received TXA vs number of patients randomized to placebo who received the placebo
- Seroma rate [ Time Frame: 3 months ]Rate of seroma formation within 3 months following mastectomy in each arm of the study.
- Seroma volume [ Time Frame: 3 months ]Amount of drainage (volume) in patients who did have a seroma, for patients in both arms of the study
- Seroma aspiration [ Time Frame: 3 months ]Aspirated volume in patients who did have a seroma, for patients in both arms of the study
- Delay in adjuvant treatment [ Time Frame: 3 months ]Time (number of weeks) of delay in adjuvant treatment due to seroma/hematoma complication, for patients in both arms of the study
- Other complications rate: Hematoma rate [ Time Frame: 3 months ]Rate of hematoma within 3 months following mastectomy in each arm of the study
- Other complications rate: Infection rate [ Time Frame: 3 months ]Rate of infection within 3 months following mastectomy in each arm of the study
- Other complications rate: Wound dehiscence rate [ Time Frame: 3 months ]Rate of wound dehiscence within 3 months following mastectomy in each arm of the study
- Daily output volume [ Time Frame: 3 months ]Daily drain output (volume), in patients in both arms of the study
- Drain discontinuation [ Time Frame: 3 months ]Time to drain discontinuation (number of days) in patients in both arms of the study
- Drain complications [ Time Frame: 3 months ]Presence of drain complications (leakage, dislodgement, blockage), in patients in both arms of the study
- Safety outcomes: rate of thromboembolic events [ Time Frame: 3 weeks ]Rate of Thromboembolic events within 3 weeks following mastectomy, in patients in both arms of the study
- Safety outcomes: rate of myocardial events [ Time Frame: 3 weeks ]
Rate of myocardial events within 3 weeks following mastectomy, in patients in both arms of the study
• Rate of other adverse events within 3 weeks following mastectomy
- Safety outcomes: rate of other adverse events [ Time Frame: 3 weeks ]Rate of other adverse events within 3 weeks following mastectomy, in patients in both arms of the study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Breast cancer diagnosis
- Age 18-80
- Fluent in English
- Female undergoing mastectomy with or without axillary intervention
Exclusion Criteria:
- Immediate reconstruction
- Pre-surgical radiation
- Known allergy to TXA
- Known thromboembolic disease
- High-risk of thromboembolism and/or receiving anticoagulants
- History of myocardial infarction (MI), transient ischemic attack or stroke within the last year
- History of subarachnoid hemorrhage
- Premenopausal women with irregular menstrual bleeding of unknown cause
- Acquired disturbances of colour vision
- Hematuria with renal cause
- History of seizure disorder
- Pregnant or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03738527
| Contact: Isabelle Duchesnay, M.D. | 905-521-2100 ext #4843 | isabelle.duchesnay@medportal.ca |
| Canada, Ontario | |
| St. Joseph's Healthcare Hamilton | Recruiting |
| Hamilton, Ontario, Canada, L8N 4A6 | |
| Juravinski Hospital - Hamilton Health Sciences | Recruiting |
| Hamilton, Ontario, Canada, L8V 1C3 | |
| Principal Investigator: | Nicole Hodgson, MD, MSc, FRCSC | Hamilton Health Sciences, McMaster University |
| Responsible Party: | Hamilton Health Sciences Corporation |
| ClinicalTrials.gov Identifier: | NCT03738527 |
| Other Study ID Numbers: |
5271 |
| First Posted: | November 13, 2018 Key Record Dates |
| Last Update Posted: | February 21, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
tranexamic acid mastectomy topical |
breast cancer seroma hematoma |
|
Hematoma Seroma Hemorrhage Pathologic Processes Inflammation Tranexamic Acid |
Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |